Evaluation of therapeutic effect of nimodipine on facial nerve injury following brain tumor surgery

Evaluation of therapeutic effect of nimodipine on facial nerve injury following cerebellar peduncle angle tumor surgery

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120527009878N8

Enrollment

Registered

2019-06-12

Start date

2019-06-22

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Faintal nerve weakness after surgery. Injury of facial nerve

Interventions

Intervention group: Subjects will be placed on the first day of postoperative post-PO surgery and will be allowed to start feeding or gavage under the semi-mediastin with g60 every 6 hours. The first

Eligibility

Sex/Gender

All

Age

No minimum to 70 Years

Inclusion criteria

Inclusion criteria: Patient with CP angle tumor with diameter less than 3 cm and postoperative facial weakness Satisfaction to participate in the study

Exclusion criteria

Exclusion criteria: Facial weakness before surgery Complete nerve disruption during surgery Large tumor diameter (over 3 cm) Tumors other than schwannoma and meningioma

Design outcomes

Primary

Measure	Time frame
The recovery pattern of the nasal fascia. Timepoint: After discharge from the operating room, 3 and 6 months after surgery. Method of measurement: House-Brackmann Score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ali Meshkini

Tabriz University of Medical Sciences

meshkinia@tbzmed.ac.ir+98 41 3334 7054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026